This is so good to hear coming out of Australia, a nation that has always led the forefront of important research and studies. The more research we have, the faster we are getting closer to cannabis reform in this country.
Researches will test the effectiveness of CogniCann, a proprietary oral cannabis spray, as a treatment for aggression and agitation caused by dementia.
“Researchers at the University of Notre Dame in Western Australia want to transform the way we treat dementia and other cognitive impairments associated with old age. And they hope their upcoming study will point the way. In partnership with MGC Pharmaceuticals, the University of Notre Dame’s Institute for Health Research is conducting the first-ever clinical trials to study cannabis as a treatment for dementia and Alzheimer’s symptoms in humans. Over 14 months, researchers will conduct a series of 16-week trials involving a total of 50 participants, all aged 65 and older. The actual clinical trials are currently slated to begin in early 2020, and Phase II is currently underway to recruit eligible participants.”
Read the full story here:
First Trials Of Cannabis Treatment For Dementia Begin in Australia